The pivotal role of the alternative NF-κB pathway in maintenance of basal bone homeostasis and osteoclastogenesis

Journal of Bone and Mineral Research

Volumn 25, Issue 4, 2010, Pages 809-818

  Soysa, Niroshani S ^a   Alles, Neil ^a   Weih, Debra ^b   Lovas, Agnes ^b   Hussain Mian, Anower ^a   Shimokawa, Hitoyata ^a   Yasuda, Hisataka ^c   Weih, Falk ^b   Jimi, Eijiro ^d   Ohya, Keiichi ^a   Aoki, Kazuhiro ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b FRITZ LIPMANN INSTITUTE   (Germany)

^c Oriental Yeast Co Ltd   (Japan)

^d KYUSHU DENTAL COLLEGE   (Japan)

Author keywords

Alymphoplasia (aly aly); NF B alternative noncanonical pathway; NIK; Osteopetrosis; P100

Indexed keywords

DNA; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN P100; PROTEIN P50; PROTEIN P52; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB;

ALLELE; ARTICLE; BONE DENSITY; BONE MASS; CELL COUNT; CONTROLLED STUDY; DNA BINDING; GENE DELETION; HOMEOSTASIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHENOTYPE; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; BONE AND BONES; BONE DENSITY; FEMALE; HOMEOSTASIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; OSTEOCLASTS; OSTEOGENESIS; OSTEOPETROSIS; RANK LIGAND; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB;

EID: 77953365526     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.091030     Document Type: Article

References (22)

1. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med. 1997;3:1285-1289. (Pubitemid 27508833)
2. Franzoso G, Carlson L, Xing L, et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 1997;11:3482-3496. (Pubitemid 28023969)
3. Soysa NS, Alles N. NF-κB functions in osteoclasts. Biochem Biophys Res Commun. 2009;378:1-5.
4. Vaira S, Johnson T, Hirbe AC, et al. RelB is the NF-kB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci USA. 2008;105:3897-3902. (Pubitemid 351723496)
5. Tucker E, O'Donnell K, Fuchsberger M, et al. A novel mutation in the Nfkb2 gene generates an NF-κB2 "super repressor". J Immunol. 2007;179:7514-7522.
6. Shinkura R, Kitada K, Matsuda F, et al. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-κB-inducing kinase. Nat Genet. 1999;22:74-77. (Pubitemid 29214808)
7. Yin L, Wu L, Wesche H, et al. Defective lymphotoxin-b receptor-induced NF-κB transcriptional activity in NIK-deficient mice. Science. 2001;291:2162-2165. (Pubitemid 32224449)
8. Novack DV, Yin L, Hagen-Stapleton A, et al. The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis. J Exp Med. 2003;198:771-781. (Pubitemid 37087776)
9. Guo F, Tanzer S, Busslinger M, Weih F. Lack of nuclear factor-κB2/p100 causes a RelB-dependent block in early B lymphopoiesis. Blood. 2008;112:551-559.
10. Ishikawa H, Carrasco D, Claudio E, Ryseck RP, Bravo R. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-κB2. J Exp Med. 1997;186:999-1014. (Pubitemid 27441145)
11. Alles N, Soysa NS, Hussain MD, et al. Polysaccharide nanogel delivery of a TNF-α and RANKL antagonist peptide allows systemic prevention of bone loss. Eur J Pharm Sci. 2009;37:83-88.
12. Saito H, Kojima T, Takahashi M, et al. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis. Arthritis Rheum. 2007;56:1164-1174. (Pubitemid 46608641)
13. Hussain Mian A, Saito H, Alles N, Shimokawa H, Aoki K, Ohya K. Lipopolysaccharide-induced bone resorption is increased in TNF type 2 receptor-deficient mice in vivo. J Bone Miner Metab. 2008; 26: 469-477.
14. Soysa NS, Alles N, Shimokawa H, Jimi E, Aoki K, Ohya K. Inhibition of the classical NF-κB pathway prevents osteoclast bone-resorbing activity. J Bone Miner Metab. 2009;27:131-139.
15. Saito H, Soysa N, Alles N, Aoki K, Ohya K. Three-Dimensional Measurements of Bone Resorption Lacunae Reveal Inhibition of Osteoclast Activity by TNF-α Antagonists In vitro. Dentistry In Japan. 2006; 42: 35-37.
16. Aoki K, Saito H, Itzstein C, et al. A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest. 2006;116:1525-1534. (Pubitemid 43911007)
17. Renard P, Ernest I, Houbion A, et al. Development of a sensitive multi-well colorimetric assay for active NF-κB. Nucleic Acids Res. 2001;29:E21.
18. Yamada T, Mitani T, Yorita K, et al. Abnormal immune function of hemopoietic cells from alymphoplasia (aly) mice, a natural strain with mutant NF-κB-inducing kinase. J Immunol. 2000;165:804-812. (Pubitemid 30484747)
19. Xiao G, Harhaj EW, Sun SC. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol Cell. 2001;7:401-409. (Pubitemid 32206507)
20. Naumann M, Nieters A, Hatada EN, Scheidereit C. NF-κB precursor p100 inhibits nuclear translocation and DNA binding of NF-κB/rel-factors. Oncogene. 1993;8:2275-2281. (Pubitemid 23226963)
21. Scheinman RI, Beg AA, Baldwin AS Jr. NF-κB p100 (Lyt-10) is a component of H2TF1 and can function as an IκB-like molecule. Mol Cell Biol. 1993;13:6089-6101.
22. Sun SC, Ganchi PA, Beraud C, Ballard DW, Greene WC. Autoregulation of the NF-κB transactivator RelA (p65) by multiple cytoplasmic inhibitors containing ankyrin motifs. Proc Natl Acad Sci USA. 1994;91:1346-1350.